right model. right insight.
Breaking News:
InVivo Biosystems appoints Kat McCormick, Ph.D. as the new CEO.
Bridge the data gap between cell culture and rodent models. Rapidly conduct preclinical studies to de-risk your clinical trial.
An expert in CRISPR genome editing for creating custom genome edited zebrafish and C. elegans, our CRISPR genome editing platform enables preclinical studies and drug discovery by providing insights you need to derisk your clinical trial or decide the next phase of product devleopment.
Sample Report
Download our sample data report to see an example of the dataset you would receive if you partnered with us.
White Paper
Our newest white paper focus on the gut microbiome and discusses the questions: What is the microbiome? How does it help or hinder health? And, what does recent research indicate?
Customer Story
Dr. Marius Galyan (CEO and Founder at Galyan Bio, Inc.) shares his experience in working with InVivo Biosystems and how the Longevity Platform delivered the results he needed to accelerate his research.
About InVivo Biosystems
2010
Year Established
45
Number of Employees
11
Number of PhDs
18
Average Years of Experience in Genetics
4000+
Number of Preclinical Models Created
247
Publications
READY TO GET STARTED?
Ready to connect with us to learn more about working with our company or our technology?
Submit your inquiry below & we will get back to you soon.
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
An expert in CRISPR genome editing, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging, developmental, and disease studies. Our unique in vivo platforms and technologies bridge the gap between cells and mice.
